Resilient Lifescience

About Resilient Lifescience

Resilient Lifescience is developing a wearable medical device that utilizes non-invasive sensing technology to automatically detect Opioid-Induced Respiratory Depression (OIRD) and administer naloxone. This device addresses the critical issue of opioid overdose deaths, particularly in situations where individuals are alone and unable to receive timely assistance.

```xml <problem> Opioid overdose is a leading cause of death, often occurring when individuals are alone and unable to receive timely administration of naloxone. Current methods for detecting respiratory depression rely on intervention by another person. </problem> <solution> Resilient Lifescience is developing a wearable medical device designed to automatically detect Opioid-Induced Respiratory Depression (OIRD) using non-invasive sensing technology. Upon detection of OIRD, the device will sound an emergency alarm and automatically administer naloxone. The Resilient System aims to provide a solution for individuals at risk of opioid overdose, particularly when they are alone, by providing automated detection and intervention. </solution> <features> - Non-invasive sensing technology for real-time monitoring of respiratory function - Automated detection of Opioid-Induced Respiratory Depression (OIRD) - Automatic naloxone administration upon OIRD detection - Emergency alarm to alert the user and potential bystanders - Wearable design for continuous monitoring in various settings </features> <target_audience> The primary target audience includes individuals who use opioids and are at risk of overdose, as well as their loved ones and caregivers. </target_audience> ```

What does Resilient Lifescience do?

Resilient Lifescience is developing a wearable medical device that utilizes non-invasive sensing technology to automatically detect Opioid-Induced Respiratory Depression (OIRD) and administer naloxone. This device addresses the critical issue of opioid overdose deaths, particularly in situations where individuals are alone and unable to receive timely assistance.

Where is Resilient Lifescience located?

Resilient Lifescience is based in Pittsburgh, United States.

When was Resilient Lifescience founded?

Resilient Lifescience was founded in 2022.

How much funding has Resilient Lifescience raised?

Resilient Lifescience has raised 830000.

Location
Pittsburgh, United States
Founded
2022
Funding
830000
Employees
5 employees
Major Investors
AlphaLab Health

Find Investable Startups and Competitors

Search thousands of startups using natural language

Resilient Lifescience

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

Resilient Lifescience is developing a wearable medical device that utilizes non-invasive sensing technology to automatically detect Opioid-Induced Respiratory Depression (OIRD) and administer naloxone. This device addresses the critical issue of opioid overdose deaths, particularly in situations where individuals are alone and unable to receive timely assistance.

resilient.bio1K+
cb
Crunchbase
Founded 2022Pittsburgh, United States

Funding

$

Estimated Funding

$500K+

Major Investors

AlphaLab Health

Team (5+)

No team information available.

Company Description

Problem

Opioid overdose is a leading cause of death, often occurring when individuals are alone and unable to receive timely administration of naloxone. Current methods for detecting respiratory depression rely on intervention by another person.

Solution

Resilient Lifescience is developing a wearable medical device designed to automatically detect Opioid-Induced Respiratory Depression (OIRD) using non-invasive sensing technology. Upon detection of OIRD, the device will sound an emergency alarm and automatically administer naloxone. The Resilient System aims to provide a solution for individuals at risk of opioid overdose, particularly when they are alone, by providing automated detection and intervention.

Features

Non-invasive sensing technology for real-time monitoring of respiratory function

Automated detection of Opioid-Induced Respiratory Depression (OIRD)

Automatic naloxone administration upon OIRD detection

Emergency alarm to alert the user and potential bystanders

Wearable design for continuous monitoring in various settings

Target Audience

The primary target audience includes individuals who use opioids and are at risk of overdose, as well as their loved ones and caregivers.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.